Covered recipient · General Payments record
IRA H THORLA
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$3,127.81
181 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,127.81 | 181 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie, Inc. | $578.32 | 20 |
| Novartis Pharmaceuticals Corporation | $471.22 | 26 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $212.14 | 22 |
| UCB, Inc. | $205.22 | 11 |
| Lilly USA, LLC | $189.02 | 12 |
| Janssen Biotech, Inc. | $169.37 | 11 |
| Regeneron Healthcare Solutions, Inc. | $148.01 | 8 |
| Celgene Corporation | $140.61 | 8 |
| PFIZER INC. | $133.94 | 13 |
| Amgen Inc. | $132.65 | 6 |
| Almirall LLC | $110.56 | 6 |
| Medimetriks Pharmaceuticals, Inc. | $70.35 | 2 |
| LEO Pharma Inc. | $69.98 | 5 |
| Galderma Laboratories, L.P. | $67.81 | 5 |
| Sun Pharmaceutical Industries Inc. | $64.01 | 3 |
| Genentech USA, Inc. | $60.24 | 4 |
| EPI Health, LLC | $56.08 | 4 |
| Mayne Pharma Inc. | $48.06 | 3 |
| GENZYME CORPORATION | $40.32 | 2 |
| DERMIRA, INC. | $37.07 | 2 |
| Promius Pharma LLC | $28.99 | 1 |
| Encore Dermatology Inc. | $23.74 | 2 |
| Merz North America, Inc. | $21.48 | 1 |
| STRATA Skin Sciences, Inc. | $20.18 | 2 |
| Mylan Pharmaceuticals Inc. | $15.80 | 1 |
| Merck Sharp & Dohme Corporation | $12.64 | 1 |
Page 4 of 4; records 151–181 of 181 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
IRA H THORLA
NPI 1730178047 · CMS profile ID 305809
Allopathic & Osteopathic Physicians / Dermatology
BATON ROUGE, LA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–181 of 181 matching records. This page contains 31 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1730178047?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- IRA H THORLA, NPI 1730178047, CMS profile ID 305809. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–181 of 181 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730178047?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). IRA H THORLA, NPI 1730178047, CMS profile ID 305809. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–181 of 181 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730178047?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- IRA H THORLA, NPI 1730178047, CMS profile ID 305809, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–181 of 181 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1730178047?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
181 matching records · $3,127.81 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–181 of 181.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Promius Pharma LLC | $28.99 | 03/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701096609 | CMS |
| Mayne Pharma Inc. | $17.86 | 02/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705526061 | CMS |
| AbbVie, Inc. | $20.45 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647855993 | CMS |
| Janssen Biotech, Inc. | $22.30 | 02/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658752427 | CMS |
| Galderma Laboratories, L.P. | $13.38 | 02/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687722909 | CMS |
| Celgene Corporation | $16.10 | 02/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672752519 | CMS |
| Novartis Pharmaceuticals Corporation | $24.42 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660040339 | CMS |
| LEO Pharma Inc. | $12.49 | 02/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687274139 | CMS |
| Mylan Pharmaceuticals Inc. | $15.80 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694776791 | CMS |
| Genentech USA, Inc. | $16.47 | 02/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681289741 | CMS |
| Sun Pharmaceutical Industries Inc. | $24.97 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704601513 | CMS |
| Lilly USA, LLC | $21.02 | 02/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657859737 | CMS |
| UCB, Inc. | $27.64 | 02/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688252841 | CMS |
| Lilly USA, LLC | $17.70 | 02/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657853017 | CMS |
| PFIZER INC. | $9.94 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673239085 | CMS |
| Regeneron Healthcare Solutions, Inc. | $21.62 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673489129 | CMS |
| Novartis Pharmaceuticals Corporation | $21.39 | 01/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660040351 | CMS |
| AbbVie, Inc. | $23.57 | 01/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647855991 | CMS |
| Medimetriks Pharmaceuticals, Inc. | $34.76 | 01/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 702111389 | CMS |
| Galderma Laboratories, L.P. | $13.75 | 01/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687722907 | CMS |
| Novartis Pharmaceuticals Corporation | $8.42 | 01/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660040387 | CMS |
| Celgene Corporation | $23.06 | 01/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672718519 | CMS |
| Janssen Biotech, Inc. | $18.10 | 01/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658752421 | CMS |
| GENZYME CORPORATION | $22.27 | 01/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694270015 | CMS |
| AbbVie, Inc. | $19.96 | 01/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647855987 | CMS |
| Genentech USA, Inc. | $12.65 | 01/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681194257 | CMS |
| Sun Pharmaceutical Industries Inc. | $20.57 | 01/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704601511 | CMS |
| Lilly USA, LLC | $16.68 | 01/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657863241 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $15.38 | 01/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684606707 | CMS |
| Novartis Pharmaceuticals Corporation | $8.32 | 01/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660040337 | CMS |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $16.00 | 01/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684606705 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $761,658.08 | 340 |
| PY2024 | Recipient | $1,797.31 | 10 |
| PY2024 | Principal investigator | $1,240,202.49 | 637 |
| PY2023 | Principal investigator | $1,174,122.40 | 468 |
| PY2022 | Principal investigator | $592,136.74 | 161 |
| PY2021 | Principal investigator | $708,330.52 | 115 |
| PY2020 | Recipient | $5,063.81 | 3 |
| PY2020 | Principal investigator | $744,803.00 | 129 |
| PY2019 | Recipient | $34,733.59 | 3 |
| PY2019 | Principal investigator | $386,356.24 | 57 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
340 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $10,083.36 | 12/31/2025 | Non-covered Recipient Entity DELRICHT RESEARCH AT TOURO MEDICAL CENTER | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202534765 |
| Principal investigator 1 | PFIZER INC. | $4,596.10 | 12/31/2025 | Non-covered Recipient Entity DelRicht LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228737623 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 12/22/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907803 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 12/22/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907807 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,400.41 | 12/22/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112748 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $16,000.00 | 12/22/2025 | Non-covered Recipient Entity Delricht LLC | A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of Brivekimig Followed by a Maintenance Period in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1226128492 |
| Principal investigator 1 | Incyte Corporation | $293.00 | 12/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240523853 |
| Principal investigator 1 | Incyte Corporation | $259.00 | 12/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240523857 |
| Principal investigator 1 | Incyte Corporation | $1,385.00 | 12/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523872 |
| Principal investigator 1 | ABBVIE INC. | $2,000.00 | 12/17/2025 | Non-covered Recipient Entity DELRICHT LLC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202531006 |
| Principal investigator 1 | Incyte Corporation | $10,000.00 | 12/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523930 |
| Principal investigator 1 | Incyte Corporation | $2,077.00 | 12/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523943 |
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 12/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524010 |
| Principal investigator 1 | Incyte Corporation | $793.00 | 12/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524047 |
| Principal investigator 1 | Incyte Corporation | $1,979.00 | 12/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524062 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 12/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524142 |
| Principal investigator 1 | Incyte Corporation | $5,000.00 | 12/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524152 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 12/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524176 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 12/16/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112476 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 12/16/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112721 |
| Principal investigator 1 | Incyte Corporation | $380.00 | 12/11/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523875 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 12/10/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523883 |
| Principal investigator 1 | Incyte Corporation | $259.00 | 12/04/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240523863 |
| Principal investigator 1 | Incyte Corporation | $293.00 | 12/04/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240523867 |
| Principal investigator 1 | Incyte Corporation | $1,604.00 | 12/04/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523879 |
| Principal investigator 1 | Incyte Corporation | $16.59 | 12/01/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523894 |
| Principal investigator 1 | Incyte Corporation | $70.00 | 12/01/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523898 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 12/01/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523906 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 12/01/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523910 |
| Principal investigator 1 | Incyte Corporation | $52.14 | 12/01/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523938 |
| Principal investigator 1 | Incyte Corporation | $264.00 | 12/01/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523974 |
| Principal investigator 1 | Incyte Corporation | $14.22 | 12/01/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523978 |
| Principal investigator 1 | Incyte Corporation | $53.20 | 12/01/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523998 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524124 |
| Principal investigator 1 | Incyte Corporation | $1,533.00 | 12/01/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524168 |
| Principal investigator 1 | Incyte Corporation | $18.96 | 12/01/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524180 |
| Principal investigator 1 | Incyte Corporation | $7.11 | 12/01/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524200 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 12/01/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524230 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,007.00 | 12/01/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112446 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 11/28/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907780 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 11/28/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907783 |
| Principal investigator 1 | Biofrontera Inc. | $100.00 | 11/27/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907736 |
| Principal investigator 1 | Biofrontera Inc. | $50.00 | 11/27/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907741 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 11/27/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907746 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 11/27/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907750 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 11/25/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523830 |
| Principal investigator 1 | Incyte Corporation | $380.00 | 11/25/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523839 |
| Principal investigator 1 | Incyte Corporation | $6,600.00 | 11/25/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523848 |
| Principal investigator 1 | Incyte Corporation | $1,736.00 | 11/24/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524002 |
| Principal investigator 1 | Incyte Corporation | $70.00 | 11/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523890 |
| Principal investigator 1 | Incyte Corporation | $446.00 | 11/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523926 |
| Principal investigator 1 | Incyte Corporation | $2,044.00 | 11/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523985 |
| Principal investigator 1 | Incyte Corporation | $133.00 | 11/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523993 |
| Principal investigator 1 | Incyte Corporation | $183.55 | 11/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524055 |
| Principal investigator 1 | Incyte Corporation | $616.00 | 11/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524093 |
| Principal investigator 1 | Incyte Corporation | $194.18 | 11/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524115 |
| Principal investigator 1 | Incyte Corporation | $26.60 | 11/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524128 |
| Principal investigator 1 | Incyte Corporation | $140.00 | 11/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524132 |
| Principal investigator 1 | Incyte Corporation | $88.00 | 11/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524137 |
| Principal investigator 1 | Incyte Corporation | $511.00 | 11/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524144 |
| Principal investigator 1 | Incyte Corporation | $1,632.00 | 11/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524148 |
| Principal investigator 1 | Incyte Corporation | $266.00 | 11/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524195 |
| Principal investigator 1 | Incyte Corporation | $1,979.00 | 11/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523934 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524006 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524018 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 11/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524030 |
| Principal investigator 1 | Incyte Corporation | $159.00 | 11/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524103 |
| Principal investigator 1 | Incyte Corporation | $159.00 | 11/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524108 |
| Principal investigator 1 | Incyte Corporation | $159.00 | 11/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524111 |
| Principal investigator 1 | Incyte Corporation | $2,065.00 | 11/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524120 |
| Principal investigator 1 | Incyte Corporation | $2,252.00 | 11/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524158 |
| Principal investigator 1 | Incyte Corporation | $2,252.00 | 11/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524164 |
| Principal investigator 1 | Incyte Corporation | $43.00 | 11/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524172 |
| Principal investigator 1 | Incyte Corporation | $3,280.00 | 11/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524183 |
| Principal investigator 1 | Incyte Corporation | $3,280.00 | 11/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524187 |
| Principal investigator 1 | Incyte Corporation | $3,280.00 | 11/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524191 |
| Principal investigator 1 | Incyte Corporation | $2,112.00 | 11/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524204 |
| Principal investigator 1 | Incyte Corporation | $2,112.00 | 11/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524209 |
| Principal investigator 1 | ABBVIE INC. | $3,054.00 | 11/17/2025 | Non-covered Recipient Entity DELRICHT LLC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202524453 |
| Principal investigator 1 | ABBVIE INC. | $3,246.00 | 11/17/2025 | Non-covered Recipient Entity DELRICHT LLC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202524459 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $7,772.54 | 11/14/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112836 |
| Principal investigator 1 | Incyte Corporation | $43.00 | 11/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523886 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 11/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523918 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 11/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523922 |
| Principal investigator 1 | Incyte Corporation | $30.00 | 11/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523981 |
| Principal investigator 1 | Incyte Corporation | $1,597.00 | 11/10/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523914 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 11/07/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523834 |
| Principal investigator 1 | Incyte Corporation | $2,464.00 | 11/07/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523844 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $33,007.81 | 10/31/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112512 |
| Principal investigator 1 | Incyte Corporation | $380.00 | 10/29/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523809 |
| Principal investigator 1 | Biofrontera Inc. | $84,601.22 | 10/24/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907681 |
| Principal investigator 1 | Biofrontera Inc. | $717.23 | 10/24/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907685 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 10/24/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907689 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 10/24/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907694 |
| Principal investigator 1 | Incyte Corporation | $1,483.00 | 10/23/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523818 |
| Principal investigator 1 | Incyte Corporation | $1,599.00 | 10/20/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524021 |
| Principal investigator 1 | Incyte Corporation | $1,599.00 | 10/20/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524026 |
| Principal investigator 1 | Incyte Corporation | $1,483.00 | 10/16/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523813 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 10/15/2025 | Non-covered Recipient Entity DELRICHT LLC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202516989 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 10/15/2025 | Non-covered Recipient Entity DELRICHT LLC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202516991 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 10/15/2025 | Non-covered Recipient Entity DELRICHT LLC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202516993 |
| Principal investigator 1 | Incyte Corporation | $86.00 | 10/15/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523947 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 10/15/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523989 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 10/13/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112818 |
| Principal investigator 1 | Incyte Corporation | $293.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240523802 |
| Principal investigator 1 | Incyte Corporation | $3,000.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523805 |
| Principal investigator 1 | Incyte Corporation | $259.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240523826 |
| Principal investigator 1 | Incyte Corporation | $1,979.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523952 |
| Principal investigator 1 | Incyte Corporation | $1,979.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523956 |
| Principal investigator 1 | Incyte Corporation | $159.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523959 |
| Principal investigator 1 | Incyte Corporation | $159.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523963 |
| Principal investigator 1 | Incyte Corporation | $159.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523967 |
| Principal investigator 1 | Incyte Corporation | $159.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523970 |
| Principal investigator 1 | Incyte Corporation | $2,252.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524034 |
| Principal investigator 1 | Incyte Corporation | $2,252.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524038 |
| Principal investigator 1 | Incyte Corporation | $2,252.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524042 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524074 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524078 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524082 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524085 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524089 |
| Principal investigator 1 | Incyte Corporation | $2,112.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524096 |
| Principal investigator 1 | Incyte Corporation | $2,112.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524100 |
| Principal investigator 1 | Incyte Corporation | $3,280.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524214 |
| Principal investigator 1 | Incyte Corporation | $3,280.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524217 |
| Principal investigator 1 | Incyte Corporation | $3,280.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524221 |
| Principal investigator 1 | Incyte Corporation | $3,280.00 | 10/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240524226 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 10/08/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907663 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 10/08/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907667 |
| Principal investigator 1 | Biofrontera Inc. | $85.00 | 10/08/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907671 |
| Principal investigator 1 | Incyte Corporation | $2,200.00 | 10/08/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524155 |
| Principal investigator 1 | Incyte Corporation | $1,385.00 | 10/03/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523822 |
| Principal investigator 1 | Incyte Corporation | $43.00 | 10/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523902 |
| Principal investigator 1 | Incyte Corporation | $2,377.00 | 10/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524014 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 10/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524051 |
| Principal investigator 1 | Incyte Corporation | $30.00 | 10/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524065 |
| Principal investigator 1 | Incyte Corporation | $1,736.00 | 10/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240524070 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $300.00 | 10/02/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112756 |
| Principal investigator 1 | Incyte Corporation | $1,385.00 | 09/23/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523709 |
| Principal investigator 1 | Incyte Corporation | $2,868.00 | 09/18/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523706 |
| Principal investigator 1 | Incyte Corporation | $1,979.00 | 09/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523717 |
| Principal investigator 1 | Incyte Corporation | $159.00 | 09/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523722 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 09/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523730 |
| Principal investigator 1 | Incyte Corporation | $3,280.00 | 09/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523734 |
| Principal investigator 1 | Incyte Corporation | $2,252.00 | 09/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523739 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 09/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523771 |
| Principal investigator 1 | Incyte Corporation | $3,280.00 | 09/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523790 |
| Principal investigator 1 | Incyte Corporation | $2,200.00 | 09/10/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523748 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 09/04/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523713 |
| Principal investigator 1 | Incyte Corporation | $552.00 | 08/26/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240523682 |
| Principal investigator 1 | Incyte Corporation | $1,604.00 | 08/26/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523693 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 08/26/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523697 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 08/22/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907591 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 08/22/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907595 |
| Principal investigator 1 | Incyte Corporation | $2,250.00 | 08/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523701 |
| Principal investigator 1 | Incyte Corporation | $446.00 | 08/20/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523743 |
| Principal investigator 1 | ABBVIE INC. | $5,021.94 | 08/14/2025 | Non-covered Recipient Entity DELRICHT LLC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202504597 |
| Principal investigator 1 | ABBVIE INC. | $123.00 | 08/14/2025 | Non-covered Recipient Entity DELRICHT LLC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202504599 |
| Principal investigator 1 | Incyte Corporation | $380.00 | 08/14/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523689 |
| Principal investigator 1 | Incyte Corporation | $30.00 | 08/13/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523767 |
| Principal investigator 1 | Incyte Corporation | $43.00 | 08/13/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523794 |
| Principal investigator 1 | Biofrontera Inc. | $1,000.00 | 08/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907558 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 08/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907561 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 08/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907566 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 08/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907570 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 08/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907574 |
| Principal investigator 1 | Incyte Corporation | $6,080.00 | 08/07/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523686 |
| Principal investigator 1 | Incyte Corporation | $2,000.00 | 08/07/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523725 |
| Principal investigator 1 | Incyte Corporation | $10,000.00 | 08/07/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. | No dispute reported | 06/30/2026 | 1240523780 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 08/06/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523745 |
| Principal investigator 1 | ABBVIE INC. | $41.00 | 08/04/2025 | Non-covered Recipient Entity DELRICHT LLC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202500940 |
| Principal investigator 1 | Incyte Corporation | $1,553.00 | 08/04/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523776 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 08/01/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523759 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 07/28/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523785 |
| Principal investigator 1 | Incyte Corporation | $1,519.00 | 07/22/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240523657 |
| Principal investigator 1 | Incyte Corporation | $2,524.00 | 07/18/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523763 |
| Principal investigator 1 | Incyte Corporation | $9,965.00 | 07/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240523660 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 07/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240523668 |
| Principal investigator 1 | Incyte Corporation | $1,483.00 | 07/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523672 |
| Principal investigator 1 | ABBVIE INC. | $5,559.33 | 07/16/2025 | Non-covered Recipient Entity DELRICHT LLC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202498402 |
| Principal investigator 1 | Incyte Corporation | $1,474.00 | 07/10/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240523664 |
| Principal investigator 1 | Incyte Corporation | $1,385.00 | 07/10/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523678 |
| Principal investigator 1 | Incyte Corporation | $1,553.00 | 07/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523755 |
| Principal investigator 1 | Incyte Corporation | $1,553.00 | 07/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523798 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 07/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907530 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 07/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907534 |
| Principal investigator 1 | PFIZER INC. | $1,103.49 | 06/26/2025 | Non-covered Recipient Entity DelRicht LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228790097 |
| Principal investigator 1 | Incyte Corporation | $1,599.00 | 06/25/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523441 |
| Principal investigator 1 | Incyte Corporation | $4,729.00 | 06/24/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523348 |
| Principal investigator 1 | Incyte Corporation | $30.00 | 06/23/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523458 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 06/23/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523587 |
| Principal investigator 1 | Incyte Corporation | $86.00 | 06/23/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523626 |
| Principal investigator 1 | ABBVIE INC. | $82.00 | 06/19/2025 | Non-covered Recipient Entity DELRICHT LLC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202492417 |
| Principal investigator 1 | Incyte Corporation | $2,537.00 | 06/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523352 |
| Principal investigator 1 | ABBVIE INC. | $9,920.19 | 06/12/2025 | Non-covered Recipient Entity DELRICHT LLC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202491281 |
| Principal investigator 1 | Incyte Corporation | $380.00 | 06/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523346 |
| Principal investigator 1 | Incyte Corporation | $761.00 | 06/11/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523470 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 06/11/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523484 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,536.45 | 06/11/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112711 |
| Principal investigator 1 | Incyte Corporation | $1,553.00 | 06/06/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523479 |
| Principal investigator 1 | Incyte Corporation | $1,553.00 | 06/06/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523653 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 06/04/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523381 |
| Principal investigator 1 | Incyte Corporation | $24.72 | 06/03/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523571 |
| Principal investigator 1 | Incyte Corporation | $2.72 | 06/03/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema | No dispute reported | 06/30/2026 | 1240523577 |
| Principal investigator 1 | Incyte Corporation | $129.00 | 06/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523462 |
| Principal investigator 1 | Incyte Corporation | $40.00 | 06/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523487 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 05/28/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523331 |
| Principal investigator 1 | Incyte Corporation | $380.00 | 05/28/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523342 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $18,420.32 | 05/28/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112618 |
| Principal investigator 1 | Incyte Corporation | $86.00 | 05/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523390 |
| Principal investigator 1 | Incyte Corporation | $60.00 | 05/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523399 |
| Principal investigator 1 | Incyte Corporation | $1,599.00 | 05/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523407 |
| Principal investigator 1 | Incyte Corporation | $1,736.00 | 05/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523622 |
| Principal investigator 1 | ABBVIE INC. | $13,062.00 | 05/16/2025 | Non-covered Recipient Entity DELRICHT LLC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202485371 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $300.00 | 05/16/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112678 |
| Principal investigator 1 | Incyte Corporation | $380.00 | 05/15/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523333 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 05/15/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523337 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,208.80 | 05/15/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112664 |
| Principal investigator 1 | PFIZER INC. | $50.00 | 05/14/2025 | Non-covered Recipient Entity DelRicht LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228783431 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $4,439.00 | 05/14/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112653 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 05/14/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112658 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $14,824.71 | 05/09/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112635 |
| Principal investigator 1 | Incyte Corporation | $1,696.00 | 05/08/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523327 |
| Principal investigator 1 | Incyte Corporation | $1,553.00 | 05/07/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523427 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $567.58 | 05/07/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112625 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 05/06/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907445 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 05/06/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907449 |
| Principal investigator 1 | PFIZER INC. | $3,502.89 | 05/06/2025 | Non-covered Recipient Entity DelRicht LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228772022 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523355 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523361 |
| Principal investigator 1 | Incyte Corporation | $113.26 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523366 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523416 |
| Principal investigator 1 | Incyte Corporation | $816.00 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523420 |
| Principal investigator 1 | Incyte Corporation | $258.00 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523423 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523431 |
| Principal investigator 1 | Incyte Corporation | $43.00 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523434 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523438 |
| Principal investigator 1 | Incyte Corporation | $1,599.00 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523446 |
| Principal investigator 1 | Incyte Corporation | $30.00 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523449 |
| Principal investigator 1 | Incyte Corporation | $86.00 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523454 |
| Principal investigator 1 | Incyte Corporation | $14.84 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523558 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523567 |
| Principal investigator 1 | Incyte Corporation | $190.00 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523582 |
| Principal investigator 1 | Incyte Corporation | $57.54 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523605 |
| Principal investigator 1 | Incyte Corporation | $57.54 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523609 |
| Principal investigator 1 | Incyte Corporation | $57.54 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523614 |
| Principal investigator 1 | Incyte Corporation | $57.54 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523618 |
| Principal investigator 1 | Incyte Corporation | $100.00 | 05/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523637 |
| Principal investigator 1 | Incyte Corporation | $380.00 | 04/28/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523308 |
| Principal investigator 1 | ABBVIE INC. | $126.00 | 04/23/2025 | Non-covered Recipient Entity DELRICHT LLC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202478671 |
| Principal investigator 1 | Eli Lilly and Company | $2,015.46 | 04/23/2025 | Non-covered Recipient Entity DELRICHT LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187878719 |
| Principal investigator 1 | Incyte Corporation | $50.00 | 04/23/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523320 |
| Principal investigator 1 | Incyte Corporation | $200.00 | 04/18/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523370 |
| Principal investigator 1 | Incyte Corporation | $30.00 | 04/18/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523374 |
| Principal investigator 1 | Incyte Corporation | $129.00 | 04/18/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523377 |
| Principal investigator 1 | Biofrontera Inc. | $24.59 | 04/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907441 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $7,764.00 | 04/17/2025 | Non-covered Recipient Entity Delricht Llc | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting | No dispute reported | 06/30/2026 | 1235997738 |
| Principal investigator 1 | ABBVIE INC. | $11,429.25 | 04/16/2025 | Non-covered Recipient Entity DELRICHT LLC | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202476986 |
| Principal investigator 1 | Incyte Corporation | $3,947.00 | 04/15/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523312 |
| Principal investigator 1 | PFIZER INC. | $2,891.09 | 04/10/2025 | Non-covered Recipient Entity DelRicht LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228780768 |
| Principal investigator 1 | Incyte Corporation | $500.00 | 04/09/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523563 |
| Principal investigator 1 | Incyte Corporation | $3,748.00 | 04/08/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523323 |
| Principal investigator 1 | Incyte Corporation | $1,553.00 | 04/07/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523386 |
| Principal investigator 1 | Incyte Corporation | $1,597.00 | 04/07/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523402 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 04/03/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907390 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 04/03/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907395 |
| Principal investigator 1 | Incyte Corporation | $1,736.00 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523394 |
| Principal investigator 1 | Incyte Corporation | $1,599.00 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523411 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523466 |
| Principal investigator 1 | Incyte Corporation | $148.85 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523475 |
| Principal investigator 1 | Incyte Corporation | $143.10 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523491 |
| Principal investigator 1 | Incyte Corporation | $63.60 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523495 |
| Principal investigator 1 | Incyte Corporation | $74.20 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523499 |
| Principal investigator 1 | Incyte Corporation | $249.08 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523503 |
| Principal investigator 1 | Incyte Corporation | $295.65 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523506 |
| Principal investigator 1 | Incyte Corporation | $114.50 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523511 |
| Principal investigator 1 | Incyte Corporation | $21.87 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523515 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523519 |
| Principal investigator 1 | Incyte Corporation | $80.90 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523524 |
| Principal investigator 1 | Incyte Corporation | $33.99 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523528 |
| Principal investigator 1 | Incyte Corporation | $541.60 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523530 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523534 |
| Principal investigator 1 | Incyte Corporation | $236.52 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523538 |
| Principal investigator 1 | Incyte Corporation | $37.66 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523542 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523545 |
| Principal investigator 1 | Incyte Corporation | $328.60 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523550 |
| Principal investigator 1 | Incyte Corporation | $32.28 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523554 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523591 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523594 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523597 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523600 |
| Principal investigator 1 | Incyte Corporation | $48.42 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523631 |
| Principal investigator 1 | Incyte Corporation | $254.40 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523640 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523646 |
| Principal investigator 1 | Incyte Corporation | $1.55 | 04/02/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523649 |
| Principal investigator 1 | Incyte Corporation | $5,611.00 | 04/01/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523317 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $11,928.92 | 03/21/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112583 |
| Principal investigator 1 | ABBVIE INC. | $630.00 | 03/20/2025 | Non-covered Recipient Entity DELRICHT LLC | M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202465023 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $300.00 | 03/18/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112566 |
| Principal investigator 1 | PFIZER INC. | $2,891.09 | 03/14/2025 | Non-covered Recipient Entity DelRicht LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228781479 |
| Principal investigator 1 | ABBVIE INC. | $11,429.25 | 03/13/2025 | Non-covered Recipient Entity DELRICHT LLC | M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202463186 |
| Principal investigator 1 | ABBVIE INC. | $752.00 | 03/12/2025 | Non-covered Recipient Entity DELRICHT LLC | M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202462664 |
| Principal investigator 1 | Incyte Corporation | $1,718.00 | 03/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523282 |
| Principal investigator 1 | Incyte Corporation | $1,553.00 | 03/12/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523289 |
| Principal investigator 1 | Incyte Corporation | $1,385.00 | 03/11/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523234 |
| Principal investigator 1 | Incyte Corporation | $3,369.00 | 03/04/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240523229 |
| Principal investigator 1 | Incyte Corporation | $1,740.00 | 03/03/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523285 |
| Principal investigator 1 | Incyte Corporation | $446.00 | 03/03/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523300 |
| Principal investigator 1 | Biofrontera Inc. | $4,153.81 | 02/28/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907354 |
| Principal investigator 1 | Biofrontera Inc. | $10,500.00 | 02/28/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907359 |
| Principal investigator 1 | Biofrontera Inc. | $500.00 | 02/28/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907363 |
| Principal investigator 1 | Incyte Corporation | $9,007.00 | 02/25/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240524246 |
| Principal investigator 1 | Incyte Corporation | $1,718.00 | 02/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523265 |
| Principal investigator 1 | Incyte Corporation | $2,200.00 | 02/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523297 |
| Principal investigator 1 | Incyte Corporation | $2,200.00 | 02/19/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523304 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $23,707.52 | 02/17/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112547 |
| Principal investigator 1 | Biofrontera Inc. | $300.00 | 02/14/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS WITH PHOTODYNAMIC THERAPY IN ADULTS | No dispute reported | 06/30/2026 | 1208907305 |
| Principal investigator 1 | ABBVIE INC. | $13,152.44 | 02/13/2025 | Non-covered Recipient Entity DELRICHT LLC | M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202451497 |
| Principal investigator 1 | Eli Lilly and Company | $74,857.69 | 02/10/2025 | Non-covered Recipient Entity DELRICHT LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | No dispute reported | 06/30/2026 | 1187879723 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 02/07/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523293 |
| Principal investigator 1 | PFIZER INC. | $724.44 | 02/06/2025 | Non-covered Recipient Entity DelRicht LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228770008 |
| Principal investigator 1 | Biofrontera Inc. | $23.99 | 01/30/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP | No dispute reported | 06/30/2026 | 1208907275 |
| Principal investigator 1 | Incyte Corporation | $2,802.00 | 01/29/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240524234 |
| Principal investigator 1 | Incyte Corporation | $2,524.00 | 01/27/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523242 |
| Principal investigator 1 | Incyte Corporation | $2,377.00 | 01/27/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523252 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 01/24/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema | No dispute reported | 06/30/2026 | 1240523269 |
| Principal investigator 1 | PFIZER INC. | $2,131.66 | 01/24/2025 | Non-covered Recipient Entity DelRicht LLC | A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228801276 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 01/23/2025 | Non-covered Recipient Entity LOUISIANA DERMATOLOGY ASSOCIATES | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 1240547963 |
| Principal investigator 1 | ABBVIE INC. | $2,041.00 | 01/22/2025 | Non-covered Recipient Entity DELRICHT LLC | M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202440581 |
| Principal investigator 1 | Incyte Corporation | $4,643.00 | 01/21/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240524238 |
| Principal investigator 1 | Incyte Corporation | $1,553.00 | 01/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523256 |
| Principal investigator 1 | Incyte Corporation | $1,684.00 | 01/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523260 |
| Principal investigator 1 | Incyte Corporation | $1,664.00 | 01/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523274 |
| Principal investigator 1 | Incyte Corporation | $1,664.00 | 01/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523278 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 01/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240524241 |
| Principal investigator 1 | Incyte Corporation | $11,130.00 | 01/17/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo | No dispute reported | 06/30/2026 | 1240524243 |
| Principal investigator 1 | ABBVIE INC. | $15,146.95 | 01/16/2025 | Non-covered Recipient Entity DELRICHT LLC | M21-417 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study | No dispute reported | 06/30/2026 | 1202439483 |
| Principal investigator 1 | Incyte Corporation | $2,377.00 | 01/15/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523238 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $300.00 | 01/09/2025 | Non-covered Recipient Entity Delricht Llc | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age | No dispute reported | 06/30/2026 | 1226112541 |
| Principal investigator 1 | Incyte Corporation | $300.00 | 01/08/2025 | Non-covered Recipient Entity DELRICHT RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240523247 |